Holistic management of patients with ALK-positive NSCLC
Holistic management of patients with ALK-positive NSCLC
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial
Prostate cancer updates: Advances in precision medicine and PARP inhibitors
Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019
Role of molecular diagnostics in prostate cancer
Key developments in pancreatic cancer from ESMO 2019
Breast cancer highlights from ESMO 2019
Melanoma highlights from ESMO 2019
ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
PARP inhibitor olaparib slows progression of advanced prostate cancer
Comment: PARP inhibitors for advanced prostate cancer